Matches in SemOpenAlex for { <https://semopenalex.org/work/W2326858971> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2326858971 endingPage "639" @default.
- W2326858971 startingPage "632" @default.
- W2326858971 abstract "Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to conventional chemotherapy. The presence of both cellular and stromal fibronectin (FN) and its interaction with integrins is necessary for PDAC progression. We tested the efficacy of endothelial monocyte-activating polypeptide II (EMAP II) to inhibit PDAC progression and its ability to interfere with FN-integrin angiogenesis signaling. In heterotopic PDAC tumors EMAP II caused a significant reduction (>65%) in tumor growth, accompanied by a >50% and 44% decrease in microvessel density and proliferative activity, respectively. EMAP II therapy caused a 62% and 56% reduction in host and tumor cell FN expression. Cultured PDAC cells expressed aVb3 and a5b1 integrins. In vitro EMAP II had limited antiproliferative effects on ASPC-1, but a pronounced antiproliferative effect on endothellial cells. 3D FN matrices increased ASPC-1 cell proliferation by > 50%, and this induction was significantly blocked by a3, a5, a6 and aV integrin funtional blocking antibodies, while a1, a2 and a4 antibodies had no effect. EMAP II also inhibited 3D FN-matrix induced ASPC-1 proliferation by >43% at 20 mM. These findings suggest that EMAP II demonstrates significant antitumor activity against PDAC cells, and that this effect may be in part mediated through targeted interference with stromal FN-integrin dependent PDAC cell proliferation." @default.
- W2326858971 created "2016-06-24" @default.
- W2326858971 creator A5006281592 @default.
- W2326858971 creator A5006708086 @default.
- W2326858971 creator A5035634684 @default.
- W2326858971 creator A5047602817 @default.
- W2326858971 creator A5055707568 @default.
- W2326858971 creator A5074895419 @default.
- W2326858971 date "2010-04-15" @default.
- W2326858971 modified "2023-09-25" @default.
- W2326858971 title "Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation" @default.
- W2326858971 doi "https://doi.org/10.4161/cbt.9.8.11265" @default.
- W2326858971 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20212356" @default.
- W2326858971 hasPublicationYear "2010" @default.
- W2326858971 type Work @default.
- W2326858971 sameAs 2326858971 @default.
- W2326858971 citedByCount "32" @default.
- W2326858971 countsByYear W23268589712012 @default.
- W2326858971 countsByYear W23268589712013 @default.
- W2326858971 countsByYear W23268589712014 @default.
- W2326858971 countsByYear W23268589712015 @default.
- W2326858971 countsByYear W23268589712016 @default.
- W2326858971 countsByYear W23268589712017 @default.
- W2326858971 countsByYear W23268589712019 @default.
- W2326858971 countsByYear W23268589712020 @default.
- W2326858971 countsByYear W23268589712022 @default.
- W2326858971 crossrefType "journal-article" @default.
- W2326858971 hasAuthorship W2326858971A5006281592 @default.
- W2326858971 hasAuthorship W2326858971A5006708086 @default.
- W2326858971 hasAuthorship W2326858971A5035634684 @default.
- W2326858971 hasAuthorship W2326858971A5047602817 @default.
- W2326858971 hasAuthorship W2326858971A5055707568 @default.
- W2326858971 hasAuthorship W2326858971A5074895419 @default.
- W2326858971 hasBestOaLocation W23268589711 @default.
- W2326858971 hasConcept C121608353 @default.
- W2326858971 hasConcept C126322002 @default.
- W2326858971 hasConcept C1491633281 @default.
- W2326858971 hasConcept C16930146 @default.
- W2326858971 hasConcept C185592680 @default.
- W2326858971 hasConcept C189165786 @default.
- W2326858971 hasConcept C195687474 @default.
- W2326858971 hasConcept C202751555 @default.
- W2326858971 hasConcept C2780210213 @default.
- W2326858971 hasConcept C2780394083 @default.
- W2326858971 hasConcept C502942594 @default.
- W2326858971 hasConcept C55493867 @default.
- W2326858971 hasConcept C62112901 @default.
- W2326858971 hasConcept C71924100 @default.
- W2326858971 hasConcept C86492073 @default.
- W2326858971 hasConcept C86803240 @default.
- W2326858971 hasConceptScore W2326858971C121608353 @default.
- W2326858971 hasConceptScore W2326858971C126322002 @default.
- W2326858971 hasConceptScore W2326858971C1491633281 @default.
- W2326858971 hasConceptScore W2326858971C16930146 @default.
- W2326858971 hasConceptScore W2326858971C185592680 @default.
- W2326858971 hasConceptScore W2326858971C189165786 @default.
- W2326858971 hasConceptScore W2326858971C195687474 @default.
- W2326858971 hasConceptScore W2326858971C202751555 @default.
- W2326858971 hasConceptScore W2326858971C2780210213 @default.
- W2326858971 hasConceptScore W2326858971C2780394083 @default.
- W2326858971 hasConceptScore W2326858971C502942594 @default.
- W2326858971 hasConceptScore W2326858971C55493867 @default.
- W2326858971 hasConceptScore W2326858971C62112901 @default.
- W2326858971 hasConceptScore W2326858971C71924100 @default.
- W2326858971 hasConceptScore W2326858971C86492073 @default.
- W2326858971 hasConceptScore W2326858971C86803240 @default.
- W2326858971 hasIssue "8" @default.
- W2326858971 hasLocation W23268589711 @default.
- W2326858971 hasLocation W23268589712 @default.
- W2326858971 hasOpenAccess W2326858971 @default.
- W2326858971 hasPrimaryLocation W23268589711 @default.
- W2326858971 hasRelatedWork W1960127412 @default.
- W2326858971 hasRelatedWork W1968907600 @default.
- W2326858971 hasRelatedWork W2002445925 @default.
- W2326858971 hasRelatedWork W2020091435 @default.
- W2326858971 hasRelatedWork W2028228455 @default.
- W2326858971 hasRelatedWork W2065961364 @default.
- W2326858971 hasRelatedWork W2102514901 @default.
- W2326858971 hasRelatedWork W2108894374 @default.
- W2326858971 hasRelatedWork W2139944756 @default.
- W2326858971 hasRelatedWork W2744164878 @default.
- W2326858971 hasVolume "9" @default.
- W2326858971 isParatext "false" @default.
- W2326858971 isRetracted "false" @default.
- W2326858971 magId "2326858971" @default.
- W2326858971 workType "article" @default.